JP7535944B2 - 神経栄養因子の誘導可能な発現のための方法及び組成物 - Google Patents

神経栄養因子の誘導可能な発現のための方法及び組成物 Download PDF

Info

Publication number
JP7535944B2
JP7535944B2 JP2020549702A JP2020549702A JP7535944B2 JP 7535944 B2 JP7535944 B2 JP 7535944B2 JP 2020549702 A JP2020549702 A JP 2020549702A JP 2020549702 A JP2020549702 A JP 2020549702A JP 7535944 B2 JP7535944 B2 JP 7535944B2
Authority
JP
Japan
Prior art keywords
cells
gdnf
promoter
expression cassette
integrated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020549702A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518365A5 (https=
JP2021518365A (ja
JPWO2019178550A5 (https=
Inventor
クライヴ スヴェンセン
ジョシュア ブレウニグ
アスラム アクタール
Original Assignee
シーダーズ－サイナイ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーダーズ－サイナイ メディカル センター filed Critical シーダーズ－サイナイ メディカル センター
Publication of JP2021518365A publication Critical patent/JP2021518365A/ja
Publication of JP2021518365A5 publication Critical patent/JP2021518365A5/ja
Publication of JPWO2019178550A5 publication Critical patent/JPWO2019178550A5/ja
Priority to JP2024047652A priority Critical patent/JP2024073654A/ja
Application granted granted Critical
Publication of JP7535944B2 publication Critical patent/JP7535944B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
JP2020549702A 2018-03-16 2019-03-15 神経栄養因子の誘導可能な発現のための方法及び組成物 Active JP7535944B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024047652A JP2024073654A (ja) 2018-03-16 2024-03-25 神経栄養因子の誘導可能な発現のための方法及び組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862644332P 2018-03-16 2018-03-16
US62/644,332 2018-03-16
US201862773752P 2018-11-30 2018-11-30
US62/773,752 2018-11-30
PCT/US2019/022595 WO2019178550A1 (en) 2018-03-16 2019-03-15 Methods and compositions for inducible expression of neurotrophic factors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024047652A Division JP2024073654A (ja) 2018-03-16 2024-03-25 神経栄養因子の誘導可能な発現のための方法及び組成物

Publications (4)

Publication Number Publication Date
JP2021518365A JP2021518365A (ja) 2021-08-02
JP2021518365A5 JP2021518365A5 (https=) 2022-02-17
JPWO2019178550A5 JPWO2019178550A5 (https=) 2022-02-17
JP7535944B2 true JP7535944B2 (ja) 2024-08-19

Family

ID=67907321

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020549702A Active JP7535944B2 (ja) 2018-03-16 2019-03-15 神経栄養因子の誘導可能な発現のための方法及び組成物
JP2024047652A Pending JP2024073654A (ja) 2018-03-16 2024-03-25 神経栄養因子の誘導可能な発現のための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024047652A Pending JP2024073654A (ja) 2018-03-16 2024-03-25 神経栄養因子の誘導可能な発現のための方法及び組成物

Country Status (7)

Country Link
US (1) US12258571B2 (https=)
EP (1) EP3765058A4 (https=)
JP (2) JP7535944B2 (https=)
KR (1) KR102843346B1 (https=)
CN (1) CN111867617A (https=)
AU (1) AU2019236288B2 (https=)
WO (1) WO2019178550A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190018000A1 (en) 2016-01-12 2019-01-17 Cedars-Sinai Medical Center A method of non destructive monitoring of biological processes in microfluidic tissue culture systems
CA3012042A1 (en) 2016-01-26 2017-08-03 Cedars-Sinai Medical Center Systems and methods for in vivo dual recombinase-mediated cassette exchange (drmce) and disease models thereof
WO2018140647A1 (en) 2017-01-25 2018-08-02 Cedars-Sinai Medical Center In vitro induction of mammary-like differentiation from human pluripotent stem cells
US11767513B2 (en) 2017-03-14 2023-09-26 Cedars-Sinai Medical Center Neuromuscular junction
US11414648B2 (en) 2017-03-24 2022-08-16 Cedars-Sinai Medical Center Methods and compositions for production of fallopian tube epithelium
US12258571B2 (en) 2018-03-16 2025-03-25 Cedars-Sinai Medical Center Methods and compositions for inducible expression of neurotrophic factors
EP4700387A2 (en) 2018-03-23 2026-02-25 Cedars-Sinai Medical Center Methods of use of islet cells
EP3775161A4 (en) 2018-04-06 2022-04-06 Cedars-Sinai Medical Center NEURODEGENERATIVE DISEASE MODELS DERIVED FROM HUMAN PLURIPOTENTIC STEM CELLS ON A MICROFLUIDIC CHIP
US11981918B2 (en) 2018-04-06 2024-05-14 Cedars-Sinai Medical Center Differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells
EP3787613B1 (en) 2018-04-30 2026-03-11 Cedars-Sinai Medical Center Pkc activation for use in treating early onset sporadic parkinson's disease
WO2020084168A1 (en) * 2018-10-26 2020-04-30 Icm (Institut Du Cerveau Et De La Moelle Épinière) Tetracycline compound for treating drug-induced dyskinesia
AU2020370288B2 (en) * 2019-10-22 2026-02-12 Cedars-Sinai Medical Center Cortical neural progenitor cells from iPSCs
US20230047254A1 (en) * 2019-12-29 2023-02-16 Gloriana Therapeutics Mammalian Cells Secreting GDNF and Their Therapeutic Use
KR20220061403A (ko) * 2020-11-06 2022-05-13 (주) 에스바이오메딕스 다능성 줄기세포 유래 신경전구세포를 포함하는 퇴행성 뇌질환 치료용 약학적 조성물
CN121420065A (zh) * 2023-06-29 2026-01-27 香港大学 用于在肝脏或肝癌中的可控转录的方法
GB202312699D0 (en) * 2023-08-18 2023-10-04 Cambridge Entpr Ltd Controllable expression in mammalian cells
WO2025091023A1 (en) * 2023-10-27 2025-05-01 Northwestern University Engineered cell transfected by all-in-one vector for therapeutic agents production and delivery and applications thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US20030084468A1 (en) 2001-09-05 2003-05-01 Economides Aris N. Methods of expressing transgenes
WO2003090689A2 (en) * 2002-04-25 2003-11-06 Wisconsin Alumni Research Foundation Neurodegenerative disorder treatment using gdnf secreting neural cells
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
US20120107284A1 (en) * 2006-06-30 2012-05-03 Elena Kozlova Stem cells for transplantation and methods for production thereof
US20100077495A1 (en) 2006-12-21 2010-03-25 Davis David P Compositions and methods for the expression of nucleic acids
US8592211B2 (en) * 2009-03-20 2013-11-26 The Rockefeller University Enhanced PiggyBac transposon and methods for transposon mutagenesis
US20120107938A1 (en) 2009-06-29 2012-05-03 University Of Basel Methods and kits for high efficiency engineering of conditional mouse alleles
WO2013155222A2 (en) * 2012-04-10 2013-10-17 The Regents Of The University Of California Brain-specific enhancers for cell-based therapy
CN102816793B (zh) * 2012-08-22 2014-09-10 陕西师范大学 单载体双向启动的Tet-on诱导表达系统及其构建方法和应用
JP2016508520A (ja) 2013-02-15 2016-03-22 インターナショナル ステム セル コーポレイション 神経変性疾患の治療のための、ヒト多能性幹細胞に由来する神経細胞の使用
US10519421B2 (en) 2013-03-21 2019-12-31 Kyoto University Induction of motor neurons from pluripotent stem cells
WO2014204724A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
WO2015143342A1 (en) 2014-03-21 2015-09-24 Cellular Dynamics International, Inc. Production of midbrain dopaminergic neurons and methods for the use thereof
CA2943296C (en) * 2014-03-21 2022-10-18 The Sydney Children's Hospitals Network (Randwick And Westmead) (Incorporating The Royal Alexandra Hospital For Children) Stable gene transfer to proliferating cells
EP3122370A1 (en) 2014-03-28 2017-02-01 Buck Institute for Research on Aging Methods and compositions for modulating the immune system
AU2015279552B2 (en) 2014-06-27 2021-01-21 Angiocrine Bioscience, Inc. Neural cells expressing adenovirus E4ORF1, and methods of making and using the same
JP6928604B2 (ja) * 2015-11-04 2021-09-01 フェイト セラピューティクス，インコーポレイテッド 万能性細胞のゲノム改変
CA3012042A1 (en) 2016-01-26 2017-08-03 Cedars-Sinai Medical Center Systems and methods for in vivo dual recombinase-mediated cassette exchange (drmce) and disease models thereof
US10221395B2 (en) 2016-06-16 2019-03-05 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
US12258571B2 (en) 2018-03-16 2025-03-25 Cedars-Sinai Medical Center Methods and compositions for inducible expression of neurotrophic factors
KR20220024527A (ko) 2019-06-17 2022-03-03 세다르스-신나이 메디칼 센터 생체내 이중 재조합효소-매개된 카세트 교환 (dRMCE)을 위한 시스템 및 방법 그리고 이들의 질환 모델

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Gene Therapy，2006年，Vol.13，pp.379-388
HUMAN GENE THERAPY，2005年，Vol.16，pp.509-521
J. Comp. Neurol.，Vol.522，2014年，pp.2707-2728
PLoS ONE，2007年，Issue 8, e689，pp.1-14
Stem Cell Reports，2015年，Vol.4，pp.323-331

Also Published As

Publication number Publication date
JP2024073654A (ja) 2024-05-29
AU2019236288B2 (en) 2025-06-05
KR102843346B1 (ko) 2025-08-06
US20210024955A1 (en) 2021-01-28
EP3765058A4 (en) 2021-12-22
US12258571B2 (en) 2025-03-25
KR20200132957A (ko) 2020-11-25
CA3092284A1 (en) 2019-09-19
JP2021518365A (ja) 2021-08-02
CN111867617A (zh) 2020-10-30
EP3765058A1 (en) 2021-01-20
AU2019236288A1 (en) 2020-09-17
WO2019178550A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
JP7535944B2 (ja) 神経栄養因子の誘導可能な発現のための方法及び組成物
CN110249045B (zh) 可控转录
JP2022553953A (ja) Ｉｐｓｃ由来の皮質神経前駆細胞
Liang et al. Neural progenitor cell survival in mouse brain can be improved by co-transplantation of helper cells expressing bFGF under doxycycline control
CN114761035A (zh) 用于体内双重组酶介导的盒式交换(dRMCE)的系统和方法及其疾病模型
US20150051267A1 (en) BICISTRONIC GENE TRANSFER TOOLS FOR DELIVERY OF miRNAS AND PROTEIN CODING SEQUENCES
Jin et al. Effective restoration of dystrophin expression in iPSC Mdx-derived muscle progenitor cells using the CRISPR/Cas9 system and homology-directed repair technology
WO2023135318A1 (en) Method for expression of a transgene of interest from neural precursor cells
Sellon et al. Recovery kinetics of dual AAV-mediated human otoferlin expression
CA3092284C (en) Methods and compositions for inducible expression of neurotrophic factors
CN114514314A (zh) 小白蛋白阳性神经细胞的制造方法、细胞及分化诱导剂
Fujimoto et al. RBP-J promotes neuronal differentiation and inhibits oligodendroglial development in adult neurogenesis
Vilaboa et al. Gene switches for deliberate regulation of transgene expression: recent advances in system development and uses
KR20220054315A (ko) 요로 상피 세포로의 유도제 및 요로 상피 세포의 유도 방법
Linesch et al. Tetracycline‐Inducible and Reversible Stable Gene Expression in Human iPSC‐Derived Neural Progenitors and in the Postnatal Mouse Brain
US20250152738A1 (en) Gpr17 promoter-based targeting and transduction of glial progenitor cells
Chaudhary et al. YY1 protein is essential for the promotion of Muller glia reprogramming and retina regeneration
Galante Factors determining competence for in vivo glia-to-neuron conversion
Shelley et al. Aslam Abbasi Akhtar, Genevieve Gowing, Naomi Kobritz, Steve E. Savinoff, Leslie Garcia, David Saxon, Noell Cho, Gibum Kim, Colton M. Tom, Hannah Park, George Lawless
JP2026505771A (ja) グリア細胞の競合的置換
Mangold Ultrasound-guided in utero lentivirus transduction of the murine nervous system to investigate nervous system disorders
Heinzelmann The role of MYT1L in brain tumor formation, progression and plasticity
HK40122856A (en) Controllable transcription
Lager Cell Reprogramming Technologies for Treatment and Understanding of Genetic Disorders of Myelin
Mersmann Gene therapy for a novel mouse model of Canavan disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201028

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230601

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230901

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240325

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240409

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240806

R150 Certificate of patent or registration of utility model

Ref document number: 7535944

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150